BiotechTube

ABP-450

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine

Trial Timeline

Oct 19, 2021 → Aug 30, 2024

NCT ID
NCT05016661

About ABP-450

ABP-450 is a phase 2 stage product being developed by AEON Biopharma for Migraine. The current trial status is terminated. This product is registered under clinical trial identifier NCT05016661. Target conditions include Migraine.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05016661Phase 2Terminated
NCT04871451Phase 2Completed

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
Lasmiditan + PlaceboEli LillyPhase 3
77
Placebo + LY2300559Eli LillyPhase 2
52
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
33
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 2
52
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Galcanezumab + ErenumabEli LillyApproved
85
Aricept (donepezil hydrochloride)EisaiPhase 2
52
E2007EisaiPhase 2
52
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
85
Galcanezumab + PlaceboEli LillyPhase 3
77
Lasmiditan + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
LasmiditanEli LillyPhase 3
77
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
52
Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
85
GalcanezumabEli LillyPre-clinical
23
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52
LY2590443 + Placebo injection + Sumatriptan + Placebo capsuleEli LillyPhase 2
52

Other Products from AEON Biopharma

ABP-450Phase 2
44
ABP-450 + PlaceboPhase 2
44
ABP-450 + PlaceboPhase 2
44